Jump to the main content block

CGU department link

College of Medicine
School of Medicine
School of Traditional Chinese Medicine
Graduate Institute of Basic Medical Sciences

153212
  1. Home

Dr. Jau-Song Yu

 

Jau-Song Yu

Jau-Song Yu

Appointment : Professor/Director of Molecular Medicine Research Center

Lab：  Proteomics & Disease Biosignature Research Laboratory

Education : Ph.D.

University/Nation：National Tsing Hua University/Taiwan, Republic of Chin

Tel: 886-3-2118800 ext 5171

E-mail : yusong@mail.cgu.edu.tw

Research website :

Research interests:

The research interests in my lab are to apply multi-omics approaches (genomics, transcriptomics, proteomics and metabolomics) to explore cancer biomarkers for early detection and to investigate novel cellular signaling networks in cell/cancer biology. Specific topics include: 

(1) Multiomic analysis of oral squamous cell carcinoma (OSCC). OSCC is a common cancer worldwide that represents a serious and growing problem in many parts of the globe, including Taiwan. However, little improvement has been made for the early detection and targeted therapy of OSCC in the past decades. Our lab leads the Molecular Medicine Research Center (MMRC) OSCC research team to participate in the International Cancer Proteogenome Consortium (ICPC), which is a part of international Cancer Moonshot program led by National Cancer Institute, USA. We apply the multi-omics approach to systemically analyze OSCC specimens (cancer tissues and adjacent non-tumor parts) using genomics (WES and Rseq), proteomics/phosphoproteomics, and metabolomics technology platform established in the MMRC, Chang Gung University. We hope to establish the first Taiwanese OSCC multi-omics blueprint which can greatly facilitate the discovery of new biology of OSCC, as well as the identification new biomarkers and/or therapeutic targets for early detection and effective treatment of OSCC.      

 

(2) R & D of clinically applicable cancer biomarkers. Cancer is one of the major death cause in the world, and delayed diagnosis of cancer represents the main reason of high mortality rate of many cancer types. We put efforts to discover cancer biomarkers from tissues, body fluids and cell lines and their verification in clinical specimens using proteomics technology platforms established in the Chang Gung University Proteomics Core Lab. We focus on four cancer types: OSCC, colorectal, pancreatic and liver cancers. Our long-term goal is to develop clinically useful biomarkers for early detection of cancer, which are expected to significantly improve human health (better patient outcome and less treatment cost). Currently, the major research outcomes for OSCC salivary biomarkers have been published in 2016/10 and 2020/8, respectively, from which a patent for OSCC detection method has been approved by several countries and transferred to a local biotech company for subsequent development of commercial assays (ELISA and rapid test). The product “Immuno-based Rapid Test for Detecting the Oral Cancer Biomarker-OCBM-1” derived from this Industry-university collaboration effort has been awarded the “2019 Taipei Biotech Awards – Technology Transfer Special Mention Award”. The OCBM-1 ELISA kit has obtained European CE marking (registration No. 00159706) on 2020/12, representing the first commercial ELISA kit invented from Taiwan for detecting oral cancer biomarker using saliva specimens. Additionally, the major research outcome for pancreatic cancer blood biomarker has been published in 2011/05, from which a patent for pancreatic cancer detection method has been approved by several countries and transferred to a local biotech company for subsequent development of commercial assays.

(3) Development of aptamer for medically important proteins. Aptamer is a kind of single chain RNA or DNA with unique 3D structure that can selectively bind to a specific target (proteins, peptides, carbohydrates, small molecules, toxins, and even live cells). Aptamer can be produced using an in vitro, PCR-based selection method called SELEX (systematic evolution of ligands by exponential enrichment), displaying high potential as a molecular tool for medically important targets. Our lab has established a high throughput SELEX platform for selecting DNA aptamers against different proteins. We focus on proteins with important clinical relevance or research utility, such as virus protein, snake venom protein, cancer biomarker, etc.

Update：2022/07/15

Publications:  

  1. Peer-reviewed papers (*corresponding author)

  1. Liu CC#, Wu CJ#, Chou TY, Liaw GW, Hsiao YC, Chu LJ, Lee CH, Wang PJ, Hsieh CH, Chen CK*, Yu JS*. (2022) Development of a monoclonal scFv against cytotoxin to neutralize cytolytic activity induced by Naja atra venom on myoblast C2C12 cells. Toxins 14, 459. https://doi.org/10.3390/toxins14070459 [PubMed]
  2. ● Li W, Wu CC, Wang S, Zhou L, Qiao L, Liu F, Zhan L, Chen H, Yu JS*, Fang J*. (2022) Identification of the target protein of the metastatic colorectal cancer-specific aptamer W3 as a biomarker by aptamer-based target cells sorting and functional characterization. Biosensors and Bioelectronics 2022 Jun 3; 213:114451. doi: 10.1016/j.bios.2022.114451. Online ahead of print. [PubMed]
  3. Wu CP*, Hung CY, Murakami M, Wu YS, Lin CL, Huang YH, Hung TH, Yu JS, Ambudkar SV. (2022) P-glycoprotein Mediates Resistance to the Anaplastic Lymphoma Kinase Inhiitor Ensartinib in Cancer Cells. Cancers (Basel). 2022 May 9;14(9):2341. doi: 10.3390/cancers14092341. [PubMed]
  4. Yen WC, Chang IYF, Chang KP, Ouyang CN, Liu CR, Tsai TL, Zhang YC, Wang YH, Yu AL, Liu H, Wu CC, Chang YS, Yu JS, Yang CY*. (2022) Genomic and molecular signatures of successful patient-derived xenografts for oral cavity squamous cell carcinoma. Frontiers in Oncology 2022 Apr 4;12:792297. doi: 10.3389/fonc.2022.792297. eCollection 2022. [PubMed]
  5. Wu YY#, Hsieh IS#, Tung CH, Weng CH, Wu JE, Yu JS, Hong TM*, Chen YL*. (2022) A novel DNA aptamer targeting lung cancer stem cells exerts a therapeutic effect by binding and neutralizing Annexin A2. Molecular Therapy-Nucleic Acids. 2022 Jan 19;27:956-968. doi: 10.1016/j.omtn.2022.01.012. eCollection 2022 Mar 8. [PubMed]
  6. Liu CC, Hsiao YC, Chu LJ, Wang PJ, Liu CH, Hsieh WC, Yu JS*. (2021) Development of antibody detection ELISA based on immunoreactive toxins and toxin-derived peptides to evaluate the neutralization potency of equine plasma against Naja atra in Taiwan. Toxins 2021 Nov 19;13(11):818. doi: 10.3390/toxins13110818. [PubMed]
  7. Hsieh YJ, Chien KY, Chang CM, Hung CY, Li L, Chiang WF, Lee CC, Chang CH, Chang YH, Yu JS*, Chen YT*. (2021) Development of a method for dansylation of metabolites using organic solvent-compatible buffer systems for amine/phenol submetabolome analysis. Analytica Chimica Acta 2022 Jan 2;1189:339218, Available online 27 October 2021 [PubMed]
  8. Lai MC*, Chen YP, Li DA, Yu JS, Hung HY, Tarn WY*. (2021) DDX3 interacts with USP9X and participates in deubiquitination of the anti-apoptotic protein MCL1. FEBS J. 2022 Feb;289(4):1043-1061. doi: 10.1111/febs.16219. Epub 2021 Oct 11. [PubMed]
  9. ● Wu CC#, Lu YT#, Yeh TS#, Chan YH, Dash S, Yu JS* (2021) Fucosylated SERPINA1 is a novel serum marker for pancreatic cancer revealed by lectin affinity capture coupled with iTRAQ-based quantitative glycoproteomics approach. Int J Mol Sci 2021 Jun 4; 22(11), 6079. doi: 10.3390/ijms22116079. [PubMed]
  10. ● Liu JC, Chen YT, Hsieh YJ, Wu CC, Huang MC, Hsu YC, Wu CT, Chen CK, Dash S, Yu JS* (2021) Association of urinary ketamine and APOA1 levels with bladder dysfunction in ketamine abusers revealed via proteomics and targeted metabolite analyses. Scientific Reports 2021 May 5;11(1):9583. doi: 10.1038/s41598-021-89089-4. [PubMed]
  11. Chiang SF+, Huang HH+, Tsai WS+, Tan BCM, Yang CY, Huang PJ, Chang IYF, Lin J, Lu PS, Chin E, Liu YH, Yu JS, Chiang JM, Hung HY, You JF, Liu H*. (2021) Comprehensive functional genomic analyses link APC somatic mutation and mRNA-miRNA networks to the clinical outcome of stage-III colorectal cancer patients. Biomedical Journal Available online 16 March 2021. doi: 10.1016/j.bj.2021.03.001
  12. Wu CP*, Hung CY, Lusvarghi S, Chang YF, Hsiao SH, Huang YH, Hung TH, Yu JS, Ambudkar SV (2021) Overexpression of human ABCB1 and ABCG2 reduces the susceptibility of cancer cells to the histone deacetylase 6-specific inhibitor citarinostat. Int J Mol Sci 2021 Mar 5; 22(5), 2592. doi: 10.3390/ijms22052592. [PubMed]
  13. Liu CC#, Yang YH#, Hsiao YC, Wang PJ, Liu JC, Liu CH, Hsieh WC, Lin CC, Yu JS* (2021) Rapid and efficient enrichment of snake venoms from human plasma by a strong cation exchange tip column to improve snakebite diagnosis. Toxins 2021 Feb 13; 13(2), 140. doi: 10.3390/toxins13020140. [PubMed]
  14. ●● Chang YT, Chu LJ, Liu YC, Chen CJ, Wu SF, Chen CH, Chang IYF, Wang JS, Wu TY, Dash S, Chiang WF, Chiu SF, Gou SB, Chien CY, Chang KP, Yu JS*. (2020) Verification of saliva matrix metalloproteinase-1 as a strong diagnostic marker of oral cavity cancer. Cancers (Basel). 2020 Aug 13; 12(8):E2273. doi: 10.3390/cancers12082273. [PubMed]
  15. Chen YT#, Chang IYF#, Kan CH, Liu YH, Kuo YP, Tseng HH, Chen HC, Liu H, Chang YS, Yu JS, Chang KP, Tan BCM*. circRNAome profiling unveils a novel oncogenic circFLNB circuit in oral cancer. (2020) Cells. 2020 Aug 10; 9(8):E1868. doi: 10.3390/cells9081868 [PubMed]
  16. ● Lin YH*, Wu CC, Su WT, Tseng PC, Hsueh YY, Hsiao YC, Chang KP, Yu JS*, Chuang YR. (2020) Target peptide enrichment microfluidic chip for rapid detection of oral squamous cell carcinoma using stable isotope standards and capture by anti-peptide antibodies. Sensors and Actuators B: Chemical 2020 Nov 1, 322:128607
  17. Wu CP*, Hung CY, Lusvarghi S, Huang YH, Tseng PJ, Hung TH, Yu JS, Ambudkar SV. (2020) Overexpression of ABCB1 and ABCG2 contributes to reduced efficacy of the PI3K/mTOR inhibitor samotolisib (LY3023414) in cancer cell lines. Biochemical Pharmacology 2020 Jul 4:114137. doi: 10.1016/j.bcp.2020.114137. [PubMed]
  18. Hsueh PC, Wu KA, Yang CY, Hsu CW, Wang CL, Hung CM, Chen YT, Yu JS, Wu CC* (2020) Metabolomic profiling of parapneumonic effusion reveals a regulatory role of dipeptides in interleukin-8 production in neutrophil-like cells. Analytica Chimica Acta 2020 Sep 1;1128:238-250. doi: 10.1016/j.aca.2020.06.022. [PubMed]
  19. Chakraborty A, Lin WC, Lin YT, Huang KJ, Wang PY, Chang YF, Wang HI, Ma KT, Wang CY, Huang XR, Lee YH, Chen BC, Hsieh YJ, Chien KY, Lin TY, Liu JL, Sung LY, Yu JS, Chang YS, Pai LM*. (2020) SNAP29 mediates the assembly of histidine-induced CTP synthase filaments in proximity to the cytokeratin network. J Cell Sci 2020 May 11;133(9):jcs240200. doi: 10.1242/jcs.240200. [PubMed]
  20. Hsiao TF#, Wang CL#, Wu YC, Feng HP, Chiu YC, Lin HY, Liu KJ, Chang GC, Chien KY, Yu JS, Yu CJ*. (2020) Integrative omics analysis reveals soluble cadherin-3 as a survival predictor and an early monitoring marker of EGFR tyrosine kinase inhibitor therapy in lung cancer. Clin Cancer Res. 2020 Jul 1;26(13):3220-3229. doi: 10.1158/1078-0432.CCR-19-3972. [PubMed]
  21. Liu CC#, Chou YS#, Chen CY, Liu KL, Huang GJ, Yu JS, Wu CJ, Liaw GW, Hsieh CH*, Chen CK*. (2020) Pathogenesis of local necrosis induced by Naja atra venom: Assessment of the neutralization ability of Taiwanese freeze-dried neurotoxic antivenom in animal models. PLOS Neglected Tropical Diseases. 2020 Feb 7;14(2):e0008054. doi: 10.1371/journal.pntd.0008054. [PubMed]
  22. ●● Hsiao YC, Lin SY, Chien KY, Chen SF, Wu CC, Chang YT, Chi LM, Chu LJ, Chiang WF, Chien CY, Chang KP, Chang YS, Yu JS* (2020) An immuno-MALDI mass spectrometry assay for the oral cancer biomarker, matrix metalloproteinase-1, in dried saliva spot samples. Anal Chim Acta 1100:118-130. doi: 10.1016/j.aca.2019.12.006. [PubMed]
  23. ● Chi LM#, Hsiao YC#, Chien KY#, Chen SF, Chuang YN, Lin SY, Wang WS, Chang IYF, Yang C, Chu LJ, Chiang WF, Chien CY, Chang YS, Chang KP*, Yu JS*. (2020) Assessment of candidate biomarkers in paired saliva and plasma samples from oral cancer patients by targeted mass spectrometry. J Proteomics. 2020 Jan 16;211:103571. doi: 10.1016/j.jprot.2019.103571. [PubMed]
  24. Lin WR*, Chiang JM, Lim SN, Su MY, Chen TH, Huang SW, Chen CW, Wu RC, Tsai CL, Lin YH, Alison MR, Hsieh SY, Yu JS, Chiu CT, Yeh CT. (2019) Dynamic bioenergetic alterations in colorectal adenomatous polyps and adenocarcinomas. EBioMedicine. 2019 Jun;44:334-345. doi: 10.1016/j.ebiom.2019.05.031. [PubMed]
  25. Yu J-S. (2019) From discovery of tyrosine phosphorylation to targeted cancer therapies: The 2018 Tang Prize in Biopharmaceutical Science. Biomedical Journal 2019 Apr; 42(2), 80-83 doi: 10.1016/j.bj.2019.03.004. (Invited article) [PubMed]
  26. Chen Y-T*, Tsai C-H, Chen C-L, Yu J-S, Chang Y-H*. (2019) Development of biomarkers of genitourinary cancer using mass spectrometry-based clinical proteomics. J. Food Drug Anal. 2019 Apr; 27(2):387-403. doi: 10.1016/j.jfda.2018.09.005. [PubMed]
  27. Chen Y-T*, Huang H-C, Hsieh Y-J, Fu S-H, Li L, Chen C-L, Chu L-J, Yu J-S. (2019) Targeting amine- and phenol-containing metabolites in urine by dansylation isotope labeling and liquid chromatography mass spectrometry for evaluation of bladder cancer biomarkers. J. Food Drug Anal. 2019 Apr; 27(2): 460-474. doi: 10.1016/ j.jfda.2018.11.008. [PubMed]
  28. Chou PH, Liao WC; Tsai KW, Chen KC Yu JS, Chen TW*. (2019) TACCO, a database connecting transcriptome alterations, pathway alterations and clinical outcomes in cancers. Scientific Reports 2019 Mar 7;9(1):3877. doi: 10.1038/s41598-019-40629-z. [PubMed]
  29. Wang P#, Geng J#, Gao J, Zhao H, Li J, Shi Y, Yang B, Xiao C, Linghu Y, Sun X, Chen X, Hong L, Qin F, Li X, Yu JS, You H, Yuan Z, Zhou D, Johnson RL, Chen L* (2019) Macrophage achieves self-protection against oxidative stress-induced ageing through Mst-Nrf2 axis. Nature Communications 2019 Feb 14;10(1):755. doi: 10.1038/s41467-019-08680-6. [PubMed]
  30. Hsu C-W#, Chen Y-T#, Hsieh Y-J, Chang K-P, Hsueh P-C, Yu J-S, Chang Y-S, Li L*, Wu C-C* (2019) Integrated analyses utilizing metabolomics and transcriptomics reveal perturbation of the polyamine pathway in oral cavity squamous cell carcinoma. Anal Chim Acta 2019 Mar 7;1050:113-122. doi: 10.1016/j.aca.2018.10.070. [PubMed]
  31. Lin Y-H*, Chang H-Y, Wu C-C, Wu C-W, Chang K-P, Yu J-S*. (2019). BRAF protein immunoprecipitation, elution, and digestion from cell extract using a microfluidic mixer for mutant BRAF protein quantification by mass spectrometry. Anal. Bioanal. Chem. 2019 Feb;411(5):1085-1094. doi: 10.1007/s00216-018-1536-2. [PubMed]
  32. Lee C-C#, Hsieh Y-J#, Chen S-W, Fu S-H, Hsu C-W, Wu C-C, Han W, Li Y, Tao H, Chang Y-S, Yu J-S, Li L*, Chang C-H*, Chen Y-T*. (2018) Bretschneider solution-induced alterations in the urine metabolome in cardiac surgery patients. Scientific Reports 2018 Dec 11;8(1):17774. [PubMed]
  33. ●● Liu C-C#, Yu J-S#, Wang P-J, Hsiao Y-C, Liu C-H, Chen Y-C, Lai P-F, Hsu C-P, Fann W-C, Lin C-C*. (2018) Development of sandwich ELISA and lateral flow strip assays for diagnosing clinically significant snakebite in Taiwan. PLOS Neglected Tropical Diseases. 2018 Dec 3;12(12):e0007014. [PubMed] #Contributed equally
  34. Lin W-C, Chakraborty A, Huang S-C, Wang P-Y, Hsieh Y-J, Chien K-Y, Lee Y-H, Chang C-C, Tang H-Y, Lin Y-T, Tung C-S, Luo J-D, Chen T-W, Lin T-Y, Cheng M-L, Chen Y-T, Yeh C-T; Liu J-L, Sung L-Y, Shiao M-S, Yu J-S, Chang Y-S, Pai L-M*. (2018) Histidine-dependent protein methylation is required for compartmentalization of CTP synthase. Cell Reports 2018 Sep 4;24(10):2733-2745.e7. [PubMed]
  35. Wu CP*, Hsieh YJ, Murakami M, Vahedi S, Hsiao SH, Yeh N, Chou AW, Li YQ, Wu YS, Yu JS, Ambudkar SV. (2018) Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines. Biochem Pharmacol. 2018 Jul 17. 155:316-325. [PubMed]
  36. Liu C-C#, Lin C-C#, Hsiao Y-C, Wang P-J, Yu J-S*. (2018) Proteomic characterization of six Taiwanese snake venoms: Identification of species-specific proteins and development of a SISCAPA-MRM assay for cobra venom factors. J. Proteomics 2018 Sep 15, 187:59-68. [PubMed]
  37. Huang Y-H, Lin K-H, Yu J-S, Wu T-J, Lee W-C, Chao C-K, Pan T-L, Yeh C-T*. (2018) Targeting HSP60 by subcutaneous injections of jetPEI/HSP60-shRNA destabilizes cytoplasmic survivin and inhibits hepatocellular carcinoma growth. Mol. Carcinog. 2018 Apr 19. 57:1087–1101. [PubMed]
  38. Chen C-T, Liu C-C, Yu J-S, Li H-H, Lai M-C*. (2018) Integrated omics profiling identifies hypoxia-regulated genes in HCT116 colon cancer cells J. Proteomics 188:139-151. [PubMed]
  39. ● Chu LJ#, Hsiao YC#, Chiang WF#, Tsai CJ, Lin SY, Chang KP, Chien CY, Yu JS*. (2018) Use of saliva protein biomarkers for diagnosis of oral cavity cancer. International Journal of Head and Neck Science June 2018; 2(2): 56-68. (Invited review article)
  40. Tsai C-H,#, Chen Y-T*,#, Chang Y-H#, Hsueh C, Liu C-Y, Chang Y-S, Chen C-L*, Yu J-S* (2018) Systematic verification of bladder cancer-associated tissue protein biomarker candidates in urine specimens. Oncotraget 2018 Jul 20;9(56):30731-30747. [PubMed]
  41. Lai YH, Liu H, Chiang WF, Chen TW, Chu LJ, Yu JS, Chen SJ, Chen HC, and Tan BC*. (2018) MiR-31-5p-ACOX1 axis enhances tumorigenic fitness in oral squamous cell carcinoma via the promigratory prostaglandin E2. Theranostics 2018 Jan 1;8(2):486-504. [PubMed]
  42. ●● Hsiao YC#, Chu LJ#, Chen YT, Chi LM, Chien KY, Chiang WF, Chang YT, Chen SF, Wang WS, Chuang YN, Lin SY, Chien CY, Chang KP, Chang YS, and Yu JS*. (2018) Variability assessment of 90 salivary proteins in intra-day and inter-day samples from healthy donors by multiple reaction monitoring-mass spectrometry. (2018) Proteomics-Clin Appl. 2018 Mar;12(2). doi: 10.1002/prca.201700039. [PubMed]
  43. Wu CC#, Lin JD#, Chen JT, Chang CM, Weng HF, Hsueh C, Chien HP and Yu JS*. (2018) Integrated analysis of fine-needle-aspiration cystic fluid proteome, cancer cell secretome, and public transcriptome datasets for papillary thyroid cancer biomarker discovery. Oncotarget 9:12079-12100. [PubMed]
  44. Liu CC, You CH, Yu JS*, Huang GJ, Liu CH, Wang PJ, and Lin CC*. (2017) Analysis of the efficacy of Taiwanese freeze neurotoxic antivenom against Southeast Asian cobra venoms through proteomics and animal model approaches. PLOS Neglected Tropical Disease. 2017 Dec 15;11(12): e0006138. [PubMed]
  45. ●● Hsiao Y-C, Chi L-M, Chien K-Y, Chiang W-F, Chen S-F, Chuang Y-N, Lin S-Y, Wu C-C, Chu LJ, Chen Y-T, Chia S-L, Chien C-Y, Chang K-P, Chang Y-S, and Yu J-S*. (2017) Development of a multiplexed assay for oral cancer candidate biomarkers using peptide immunoaffinity enrichment and targeted mass spectrometry. Mol. Cell. Proteomics 2017 Oct;16(10):1829-1849. [PubMed]
  46. ●● Chen TW#, Lee CC#, Liu H#, Wu CS#, Pickering CR#, Huang PJ, Wang J, Chang IY, Yeh YM, Chen CD, Li HP, Luo JD, Tan BC, Chan TEH, Hsueh C, Chu LJ, Chen YT, Zhang B, Yang CY, Wu CC, Hsu CW, See LC, Tang P, Yu JS, Liao WC, Chiang WF, Rodriguez H, Myers JN, Chang KP*, Chang YS*. (2017) APOBEC3A is an oral cancer prognostic biomarker in carriers of an APOBEC deletion polymorphism. Nature Communications. 2017 Sep 6;8(1):465. [PubMed]
  47. ● Hsiao YC#, Chu LJ#, Chen JT, Yeh TS and Yu JS*. (2017) Proteomic profiling of the cancer cell secretome: informing clinical research. Expert Review of Proteomics (Invited review article) 2017 Sep;14(9):737-756. [PubMed]
  48. ●● Peng Y#, Zhang M#, Zheng L#, Liang Q#, Li H#, Chen J-T, Guo H, Yoshina S, Chen Y-Z, Zhao X, Wu X, Liu B, Mitani S, Yu J-S, Ding Xue*. (2017) Cysteine protease cathepsin B mediates radiation-induced bystander effects. Nature 547(7664), 458–462 (27 July 2017) [PubMed]
  49. Cheng JC*, Tseng CP, Liao MH, Peng CY, Yu JS, Chuang PH, Huang JT, Chen JJW. (2017) Activation of hepatic stellate cells by the ubiquitin C-terminal hydrolase 1 protein secreted from hepatitis C virus-infected hepatocytes. Scientific Reports. 2017 June 30;7:4448. doi:10.1038/s41598-017-04259-7 [PubMed]
  50. ● Hsieh Y-J#, Chien K-Y#, Yang I-F, Lee I-N, Wu C-C, Huang T-Y, and Yu J-S* (2017) Oxidation of protein-bound methionine in Photofrin-photodynamic therapy-treated human tumor cells explored by methionine-containing peptide enrichment and quantitative proteomics approach. Scientific Reports 2017 May 2;7(1):1370. doi: 10.1038/s41598-017-01409-9. [PubMed]
  51. Shao CH, Chen CL, Lin JY, Chen CJ, Fu SH, Chen YT, Chang YS, Yu JS, Tsui KH, Juo CG*, Wu KP*. (2017) Metabolite marker discovery for the detection of bladder cancer by comparative metabolomics. Oncotarget. 2017 Mar 21. 2017; 8:38802-38810 doi: 10.18632/oncotarget.16393. [PubMed]
  52. Chen Y-T*, Chen H-W, Wu C-F, Chu L-J, Chiang W-F, Wu C-C, Yu J-S, Tsai C-H, Liang K-H, Chang Y-S, Wu M, Ou Yang W-T. (2017) Development of a multiplexed LC-MRM/MS method for evaluation of salivary proteins as oral cancer biomarkers. Mol. Cell. Proteomics 2017 May;16(5):799-811. [PubMed]
  53. ● Lin YT, Chien KY, Wu CC, Chang WY, Chu LJ, Yeh CT*, Yu JS*. (2017) Super-SILAC mix coupled with SIM/AIMS assays for targeted verification of phosphopeptides discovered in a large-scale phosphoproteome analysis of hepatocellular carcinoma. J. Proteomics. 2017 Mar 22;157:40-51. [PubMed]
  54. Chung I-C, OuYang C-N, Yuan S-N, Li H-P, Chen J-T, Shieh H-R, Chen Y-J, Ojcius DM, Yu J-S, Chang Y-S, Chen L-C*. (2016) Pyk2 activates the NLRP3 inflammasome by directly phosphorylating ASC and contributes to inflammasome-dependent peritonitis. Scientific Reports 2016 Oct 31; 6:36214. [PubMed]
  55. ●● Yu JS#, Chen YT#, Chiang WF#, Hsiao YC#, Chu LJ#, See LC, Wu CS, Tu HT, Chen HW, Chen CC, Liao WC, Chang YT, Wu CC, Lin CY, Liu SY, Chiou ST, Cha SL, Chang KP, Chien CY, Chang SW, Chang CJ, Young JD, Pao CC, Chang YS*, Hartwell LH* (2016) Saliva Protein Biomarkers to Detect Oral Squamous Cell Carcinoma in a High-Risk Population in Taiwan. Proc Natl Acad Sci USA. 2016 Oct 11;113(41):11549-11554. (#Co-first authors) [PubMed]
  56. Hsu CH, Hsu CW, Hsueh C, Wang CL, Wu YC, Wu CC, Liu CC, Yu JS, Chang YS, Yu CJ.* (2016) Identification and characterization of potential biomarkers by quantitative tissue proteomics of primary lung adenocarcinoma. Mol. Cell. Proteomics 2016 Jul;15(7):2396-410. [PubMed]
  57. ● Chen H#, Hsiao Y-C#, Chiang S-F, Wu C-C, Lin Y-T, Liu H, Zhao H, Chen J-S, Chang Y-S, and Yu J-S*. (2016) Quantitative analysis of wild-type and V600E mutant BRAF proteins in colorectal carcinoma using immunoenrichment and targeted mass spectrometry. Anal. Chim. Acta 2016 Aug 24; 933:144-55. [PubMed]
  58. Wang C-I, Chan Y-Y, Wang C-L, Yu J-S, Chang Y-S, and Yu C-J*. (2016) mTOR regulates proteasomal degradation and Dp1/E2F1-mediated transcription of KPNA2 in lung cancer cells. Oncotarget 2016 May 3;7(18):25432-42. [PubMed]
  59. Wu C-P*, Hsieh Y-J, Hsiao S-H, Su C-Y, Li Y-Q, Huang Y-H, Huang C-W, Hsieh C-H, Yu J-S and Wu Y-S*. (2016) Human ATP-Binding Cassette transporter ABCG2 confers resistance to CUDC-907, a dual inhibitor of histone deacetylase and phosphatidylinositol 3-kinase. Mol. Pharm. 2016 Mar 7;13(3):784-94. [PubMed]
  60. Chiang S-F, Kan C-Y, Hsiao Y-C, Tang R, Hsieh L-L, Chiang J-M, Tsai W-S, Yeh C-Y, Hsieh P-S, Liang Y, Chen J-S, Yu J-S* (2015) Bone marrow stromal antigen 2 is a novel plasma biomarker and prognosticator for colorectal carcinoma — A secretome-based verification study. Disease Markers 2015; 2015:874054. [PubMed]
  61. Chen C-L, Chung T, Wu C-C, Ng K-F, Yu J-S, Tsai C-H, Chang Y-S, Liang Y, Chen Y-T* (2015) Comparative tissue proteomics of microdissected specimens reveals novel candidate biomarkers of bladder cancer. Mol Cell Proteomics. 2015 Sep;14(9):2466-78. [PubMed]
  62. Lee C-W, Chang K-P, Chen Y-Y, Liang Y, Hsueh C, Yu J-S, Chang Y-S, and Yu C-J*. (2015) Overexpressed tryptophanyl-tRNA synthetase, an angiostatic protein, enhances oral cancer cell invasiveness. Oncotarget. 2015 Sep 8;6(26):21979-92. [PubMed]
  63. Chang K-P, Lin S-J, Liu S-C, Yi J-S, Chien K-Y, Chi L-M, Kao H-K, Liang Y, Lin Y-T, Chang Y-S, Yu J-S* (2015) Low-molecular-mass secretome profiling identifies HMGA2 and MIF as prognostic biomarkers for oral cavity squamous cell carcinoma. Scientific Reports 2015 Jul 3; 5:11689. [PubMed]
  64. Kuo R-L*, Lin Y-H, Robert Wang R.Y-L, Hsu C-W, Chiu Y-T, Huang H-I, Kao L-T, Yu J-S, Shih S-R, and Wu C-C* (2015) Proteomics analysis for EV71-infected cells reveals the involvement of host protein NEDD4L in EV71 replication. J. Proteome Res. 2015 Apr 3;14(4):1818-30. [PubMed]
  65. Wang C-I, Wang C-L, Wu Y-C, Feng H-P, Liu P-J, Chang Y-S, Yu J-S, and Yu C-J* (2015) Quantitative proteomics reveals a novel role of karyopherin alpha 2 (KPNA2) in cell migration through the regulation of vimentin-pErk protein complex levels in lung cancer. J. Proteome Res. 2015 Apr 3;14(4):1739-51. [PubMed]
  66. Wu H, Wei L, Fan F, Ji S, Zhang S, Geng J, Hong L, Fan X, Chen Q, Tian J, Jiang M, Sun X, Jin C, Yin YZ, Liu Q, Zhang J, Qin F, Lin KH, Yu JS, Deng X, Wang HR, Zhao B, Johnson RL, Chen L*, Zhou D* (2015) Integration of Hippo signaling and the unfolded protein response to restrain liver overgrowth and tumorigenesis. Nat. Commun. 2015 Feb 19; 6:6239. [PubMed]
  67. Liu PJ, Chen CD, Wang CL, Wu YC, Hsu CW, Lee CW, Huang LH, Yu JS, Chang YS, Wu CC*, Yu CJ.* (2015) In-depth proteomic analysis of six types of exudative pleural effusions for non-small cell lung cancer biomarker discovery. Mol. Cell Proteomics. 2015 Apr;14(4):917-32. doi: 10.1074/mcp.M114.045914. [PubMed]
  68. Chao M*, Wang HN, Lu YJ, Chang YS, Yu JS (2015) A V-val subtype Epstein-Barr virus nuclear antigen 1 promotes cell survival after serum withdrawal. Oncol. Rep. 33(2):958-66. [PubMed]
  69. Gopinath RK†, You ST†, Chien KY†, Swamy KB, Yu JS, Schuyler SC*, Leu JY* (2014) The Hsp90-dependent proteome is conserved and enriched for hub proteins with high levels of protein-protein connectivity. Genome Biol. Evol. 6(10):2851–2865. [PudMed]
  70. Chiang S-F, Tsai M-H, Tang R, Hsieh L-L, Chiang J-M, Yeh C-Y, Hsieh P-S, Tsai W-S, Liu Y-P, Liang Y, Chen J-S* and Yu J-S* (2014) Membrane proteins as potential colon cancer biomarkers: verification of 4 candidates from a secretome dataset. Surgical Science 5(10), 418-438. [Link out]
  71. ● Hsu R-M, Hiesh Y-J, Yang T-H, Chiang Y-C, Kan C-Y, Lin Y-T, Chen J-T, and Yu J-S*. (2014) Binding of the extreme carboxyl-terminus of PAK-interacting exchange factor β (βPIX) to myosin 18A (MYO18A) is required for epithelial cell migration. BBA-Mol Cell Res. 1843 (11), 2513-2527. [PubMed]
  72. Juo C-G*, Chen C-L, Fu S-H, Lin S-T, Chen Y-T, Chang Y-S, and Yu J-S. (2014) Mass accuracy improvement of reversed-phase liquid chromatography/electrospray ionization mass spectrometry based urinary metabolomic analysis by post-run calibration using sodium formate cluster ions. Rapid Commun Mass Spectrom 28(16), 1813–1820. [PubMed]
  73. Wu C-C*#, Chang Y-T#, Chang K-P, Liu Y-L, Liu H-P, Lee I-L, Yu J-S, and Chiang W-F*. (2014) Salivary auto-antibodies as noninvasive diagnostic markers of oral cavity squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2014 Aug;23(8):1569-78. doi: 10.1158/1055-9965.EPI-13-1269. [PubMed]
  74. Fang K-H, Kao H-K, Chi L-M, Liang Y, Liu S-C, Hseuh C, Liao C-T, Yen T-C, Yu J-S, Chang K-P*. (2014) Overexpression of BST2 is associated with nodal metastasis and poorer prognosis in oral cavity cancer. Laryngoscope 2014 Sep;124(9):E354-60. [PubMed]
  75. ●● Chen C-D, Wang C-L, Yu C-J, Chien K-Y, Chen Y-T, Chen M-C, Chang Y-S, Wu C-C*, and Yu J-S* (2014) Targeted proteomic pipeline reveals diagnostic biomarkers for malignant pleural effusion of lung cancer. J. Proteome Res. 2014 Jun 6; 13(6):2818-29. [PubMed]
  76. Hsu C-W, Yu J-S, Peng P-H, Liu S-C, Chang Y-S, Chang K-P*, and Wu C-C* (2014) Secretomic profiling of primary cells reveals THBS2 as a salivary biomarker of oral cavity squamous cell carcinoma. J. Proteome Res. 2014 Nov 7;13(11):4796-807. [PubMed]
  77. Wang H-J, Hsieh Y-J, Cheng W-C, Lin C-P, Lin Y, Yang S-F, Chen C-C, Izumiya Y, Yu J-S, Kung H-J*, Wang W-C*. (2014) JMJD5 regulates PKM2 nuclear translocation and reprograms HIF-1α-mediated glucose metabolism. Proc Natl Acad Sci USA 2014 Jan 7; 111(1):279-84. [PubMed]
  78. Tseng S-P, Teng S-H, Lee P-S, Wang C-F, Yu J-S, Lu P-L*. (2013) Rapid identification of M. abscessus and M. massiliense by MALDI-TOF mass spectrometry with a comparison to sequencing methods and antimicrobial susceptibility patterns. Future Microbiol. 2013 Nov; 8:1381-9. [PubMed]
  79. Lin S-J, Chang K-P, Hsu C-W, Chi L-M, Chien K-Y, Liang Y, Tsai M-H, Lin Y-T, Yu J-S*. (2013) Low-molecular-mass secretome profiling identifies C-C motif chemokine 5 as a potential plasma biomarker and therapeutic target for nasopharyngeal carcinoma. J. Proteomics 2013 Dec 6; 94, 186-201. [PubMed]
  80. Chen J-T, Ho C-W, Chi L-M, Chien K-Y, Hsieh Y-J, Lin S-J, Yu J-S*. (2013) Identification of the P-STM antibody-recognizable phosphoepitope on lamins A/C in mitotic HeLa S3 cells. BMC Biochem. 14(1):18. [PubMed]
  81. Chang K-P, Wang C-L A, Kao H-K, Liang Y, Liu S-C, Huang L-L, Hseuh C, Hsieh Y-J, Chien K-Y, Chang Y-S, Yu J-S, Chi L-M*. (2013) Overexpression of caldesmon is associated with nodal metastasis and poorer prognosis in oral cavity squamous cell carcinomas. Cancer 119, 4003-11. 2013 Aug 20. doi: 10.1002/cncr.28300. [PubMed]
  82. Wang RY*, Kuo R-L, Ma W-C, Huang H-I, Yu J-S, Yen S-M, and Huang C-R, Shih S-R (2013) Heat shock protein-90-beta facilitates enterovirus 71 viral particles assembly. Virology 443(2):236-47. [PubMed]
  83. Chen C-L, Lin T-S, Tsai C-H, Wu C-C, Chung T, Chien K-Y, Wu M, Chang Y-S, Yu J-S*, and Chen Y-T* (2013) Identification of potential bladder cancer markers in urine by abundant-protein depletion coupled with quantitative proteomics. J. Proteomics 85:28-43. doi: 10.1016/j.jprot.2013.04.024. [PubMed]
  84. Lin Y-H*, Chen Y-J, Lai C-S*, Chen Y-T, Chen C-L, Yu J-S, and Chang Y-S (2013) A negative-pressure-driven microfluidic chip for the rapid detection of a bladder cancer biomarker in urine using bead-based ELISA. Biomicrofluidics 7 (2), 024103 [PubMed]
  85. Dong Y-M, Chien K-Y, Cheng J-T, Wang TCV, Lin S-J, Yu J-S* (2013) Site-specific separation and detection of phosphopeptide isomers with pH-mediated stacking capillary zone electrophoresis-coupled electrospray ionization-tandem mass spectrometry. J. Sep. Sci. 36(9-10):1582-9. [PubMed]
  86. Hsuuw Y-D, Chan W-H*, Yu J-S (2013) Ochratoxin A inhibits mouse embryonic development by activating a mitochondrion-dependent apoptotic signaling pathway. Int. J. Mol. Sci. 2013 Jan 7;14(1):935-53. [PudMed]
  87. Chen L-C, Liu M-Y, Hsiao Y-C, Choong W-K, Wu H-Y, Hsu W-L, Liao P-C*, Sung T-Y*, Tsai S-F*, Yu J-S*, Chen Y-J* (2013) Decoding the disease-associated proteins encoded in the human Chromosome 4. J Proteome Res. 12(1):33-44. [PubMed]
  88. Chen C-L, Lai Y-F, Tang P, Chien K-Y, Yu J-S, Tsai C-H, Chen H-W, Wu C-C, Chung T, Hsu C-W, Chen C-D, Chang Y-S, Chang P-L, and Chen Y-T*. (2012) Comparative and targeted proteomic analyses of urinary microparticles from bladder cancer and hernia patients. J. Proteome Res. 11(12):5611-29. [PubMed]
  89. ● Chang Y-F#, Yu J-S#, Chang Y-T, Su L-C, Li Y-C, Wu C-C, Chang Y-S, Lai C-S, Chou C* (2013). The utility of a high-throughput scanning biosensor in the detection of the pancreatic cancer marker ULBP2. Biosens. Bioelectron. 2013 Mar 15; 41, 232-237. [PubMed] #Equal contributions
  90. Hsueh C*, Lin J-D, Chang Y-S, Hsueh S, Chao T-C, Yu J-S, Jung S-M, Tseng N-M, Sun J-H, Kuo S-Y. (2013) Prognostic significance of expression of pituitary tumor-transforming gene-binding factor (PBF) in papillary thyroid carcinoma. Clin. Endocrinol. (Oxf) 2013 Feb;78(2):303-9. [PubMed]
  91. Wang C-I, Chien K-Y, Wang C-L, Liu H-P, Cheng C-C, Chang Y-S, Yu J-S, and Yu C-J*. (2012) Quantitative proteomics reveals regulation of KPNA2 and its potential novel cargo proteins in non-small cell lung cancer. Mol. Cell. Proteomics 2012 Nov; 11(11):1105-22. [PubMed]
  92. ● Hsieh Y-J, Chien K-Y, Lin S-Y, Sabu S, Hsu R-M, Chi L-M, Lyu P-C, and Yu J-S*. (2012) Photofrin binds to procaspase-3 and mediates photodynamic treatment–triggered methionine oxidation and inactivation of procaspase-3. Cell Death Dis. 3: e347; doi:10.1038/cddis.2012.85. July 12 2012 [PubMed]
  93. Wang I-S, Lu T-F, Lue C-E, Huang C-H, Yang P, Lin Y-T, Pijanswska DG, Yang C-M, Wang J-C, Yu J-S, Chang Y-S, and Lai C-S* (2012). Immobilization of enzyme and antibody on ALD-HfO2 EIS structure by NH3 plasma treatment. Nanoscale Res. Lett. 7, 179. [PubMed]
  94. Pan T-L*, Wang P-W, Huang C-C, Yeh C-T, Hu T-H, Yu J-S. (2012) Network analysis and proteomic identification of vimentin as a key regulator associated with the invasiveness and metastasis of human hepatocellular carcinoma cells. J. Proteomics 75(15):4676-92. [PubMed]
  95. ●● Chen Y-T, Chen H-W, Smith DS, Liang K-H, Wu C-C, Chen C-L, Chung T, Chen M-C, Chang Y-S, Borchers CH*, Yu J-S* (2012) Multiplexed quantification of 63 proteins by multiple reaction monitoring-based mass spectrometry in human urine for discovery of potential bladder cancer biomarkers. J. Proteomics 75(12):3529-45. [PubMed]
  96. ● Tsai M-H, Wu C-C, Peng P-H , Liang Y, Shiao Y-C, Chien K-Y, Chen J-T, Lin S-J, Tang R-P, Hsieh L-L*, Yu J-S* (2012) Identification of secretory gelsolin as a plasma biomarker associated with distant organ metastasis of colorectal cancer. J. Mol. Med. (Berl) 90(2), 187-200. [PubMed]
  97. Chang K-P, Yu J-S, Chien K-Y, Lee C-W, Liang Y, Liao C-T, Yen T-C, Lee L-Y, Huang L-L, Liu S-C, Chang Y-S, Chi L-M*. (2011) Identification of PRDX4 and P4HA2 as metastasis-associated proteins in oral cavity squamous cell carcinoma by comparative tissue proteomics of microdissected specimens using iTRAQ technology. J. Proteome Res. 2011 Nov 4;10(11):4935-47. [PubMed]
  98. Yu C-J*, Wang C-L, Wang C-I, Chen C-D, Dan Y-M, Wu C-C, Wu Y-C, Lee I-N, Tsai Y-H, Chang J-S and Yu J-S. (2011) Comprehensive proteome analysis of malignant pleural effusion for lung cancer biomarker discovery by using multidimensional protein identification technology. J. Proteome Res. 10(10):4671-82. [PubMed]
  99. Martel J, Young D, Young A, Wu C-Y, Chen C-D, Yu J-S, Young JD*. (2011) Comprehensive proteomic analysis of mineral nanoparticles derived from human body fluids and analyzed by liquid chromatography-tandem mass spectrometry. Anal. Biochem. 418(1):111-25. [PubMed]
  100. Yu C-J, Chang K-P, Chang Y-J, Hsu C-W, Liang Y, Yu J-S, Chi L-M, Chang Y-S, and Wu C-C*. (2011) Identification of guanylate-binding protein 1 as a potential oral cancer marker involved in cell invasion using omics-based analysis. J. Proteome Res. 10(8):3778-88. [PubMed]
  101. ● Chang Y-T, Wu C-C*, Shyr Y-M, Chen T-C, Hwang T-L, Yeh T-S, Chang K-P, Liu H-P, Liu-Y-L, Tsai, M-H, Chang Y-S, and Yu J-S*. (2011) Secretome-based identification of ULBP2 as a novel serum marker for pancreatic cancer detection. PLoS ONE 6(5), e20029. [PubMed]
  102. Peng P-H, Wu C-C*, Liu S-C, Chang K-P, Chen C-D, Chang Y-T, Hsu C-W, Chang Y-S, and Yu J-S* (2011) Quantitative plasma proteome analysis reveals aberrant level of blood coagulation-related proteins in nasopharyngeal carcinoma. J. Proteomics 2011 May 1;74(5):744-57. [PubMed]
  103. Chang K-P, Chang Y-T , Liao C-T, Yen T-C, Chen I-H, Chang Y-L, Liu Y-L, Chang Y-S, Yu J-S* and Wu C-C*. (2011) Prognostic cytokine markers in peripheral blood for oral cavity squamous cell carcinoma identified by multiplexed immunobead-based profiling. Clin. Chim. Acta. 2011 May 12;412(11-12):980-7. [PubMed]
  104. Fan CW, Chan CC, Chen KT, Twu J, Huang YS, Han CL, Chen YJ, Yu JS, Chang YS, Kuo YB, Chan EC*. (2011) Identification of SEC61β and its autoantibody as biomarkers for colorectal cancer. Clin. Chim. Acta. 2011 May 12;412(11-12):887-93. [PubMed]
  105. Han C-L, Chen J-S, Chan E-C, Wu C-P, Yu K-H, Chen K-T, Tsou C-C, Tsai C-F, Chien C-W, Kuo Y-B, Lin P-Y, Yu J-S, Hsueh C, Chen M-C, Chan C-C, Chang Y-S, Chen Y-J. An informatics-assisted label-free approach for personalized tissue membrane proteomics: Case study on colorectal cancer. Mol. Cell. Proteomics 2011 Apr;10(4):M110.003087. [PubMed]
  106. Hsueh C, Lin J-D*, Wu I-C, Chao T-C, Yu J-S, Liou M-J, Yeh C-J. (2011) Angiogenesis in papillary thyroid carcinoma: Expression of vascular endothelial growth factor, angiopoietin-1 angiogoitin-2 and Tie-2 correlated with tumor progression and prognosis J. Sur. Oncol. 103(5):395-9. [PubMed]
  107. Chang K-P, Kao H-K; Yen T-C, Chang Y-L, Liang Y, Liu S-C, Lee L-Y, Chang Y-L, Kang C-J, Chen I-H, Liao C-T*, Yu J-S*. (2011) Overexpression of macrophage inflammatory protein-3 in oral cavity squamous cell carcinoma associated with tumor metastasis. Oral Oncol. 47, 108–113. [PubMed]
  108. Kuo YB, Fan CW, Chan CC, Hung RP, Hung YS, Chen KT, Chang CA, Yu JS, Chang YS, Chan EC*. (2011) Identification of Phospholipid Scramblase 1 as a biomarker and it's prognostic value for Colorectal Cancer. Mol. Med. 17(1-2):41-47. [PubMed]
  109. ● Mapes J, Chen J-T, Yu J-S and Xue D*. (2010) Somatic sex determination in C. elegans is modulated by SUP-26 repression of tra-2 translation. Proc Natl Acad Sci USA 2010 Oct 19;107(42):18022-7. [PubMed]
  110. ●● Chen Y-T*, Chen C-L, Chen H-W, Chung T, Wu C-C, Chen C-D, Hsu C-W, Chen M-C, Tsui K-H, Chang P-L, Chang Y-S, Yu J-S*. (2010) Discovery of novel bladder cancer biomarkers by comparative urine proteomics using iTRAQ technology. J. Proteome Res. 9(11):5803-15. [PubMed]
  111. Chen J-S, Chou Y-P, Chen K-T, Hung R-P, Yu J-S, Chang Y-S, Chan E-C*. (2011) Detection of annexin A autoantibodies in sera from colorectal cancer patients. J. Clin. Gastroenterol. 45(2):125-32. [PudMed]
  112. Wang C-I, Wang C-L, Wang C-W, Chen C-D, Wu C-C, Tsai Y-H, Chang Y-S, Yu J-S, and Yu C-J*. (2011) Importin subunit alpha-2 is identified as a potential biomarker for non-small cell lung cancer by integration of cancer cell secretome and tissue transcriptome. Int. J. Cancer 128(10):2364-72. [PudMed]
  113. Liu H-P, Wu C-C, Kao H-Y, Huang Y-C, Liang Y, Chen C-C, Yu J-S, Chang Y-S*. (2010) Proteome-wide dysregulation by PRA1 depletion delineates a role of PRA1 in lipid transport and cell migration. Mol. Cell. Proteomics 2011 Mar;10(3):M900641MCP200. [PubMed]
  114. Hsieh Y-J, Yu J-S* and Lyu P-C*. (2010) Characterization of the photodynamic therapy-elicited responses of A431 cells with intracellular organelle-localized Photofrin. J. Cell. Biochem. 2010 Nov 1, 111(4):821-33. [PubMed]
  115. Chang K-P, Chang Y-T, Wu C-C, Liu Y-L, Chen M-C, Tsang N-M, Hsu C-L, Chang Y-S, and Yu J-S*. (2011) Multiplexed immunobead-based profiling of cytokine markers for detection of nasopharyngeal carcinoma and prognosis of patient survival. Head & Neck 2011 Jun;33(6):886-97. [PubMed]
  116. Chen, J-S, Chen, K-T, Fan C-W, Han C-L, Chen Y-J, Yu J-S, Chang Y-S, Chien C-W, Wu C-P, Hung R-P, Chan E-C*. (2010) Comparison of membrane fraction proteomic profiles of normal and cancerous human colorectal tissues with gel-assisted digestion and iTRAQ labeling mass spectrometry. FEBS J. 277(14), 3028-38. [PubMed]
  117. Lin C-J, Cheng M-L, Ho H-Y, You T-H, Yu J-S*, and Chiu DT-Y.* (2010) Impaired dephosphorylation process renders G6PD-deficient cells more susceptible to H2O2-induced apoptosis. Free Radic. Biol. Med. 49(3), 361–373. [PubMed]
  118. Kao H-K, Guo L-F, Cheng M-H, Chen I-H, Liao C-T, Fang K-H, Yu J-S, Chang K-P*. (2011) Predicting postoperative morbidity and mortality by model for end-stage live disease score for patients with head and neck cancer and liver cirrhosis. Head & Neck 33(4):529-34. [PubMed]
  119. Chang K-P, Wu C-C, Chen H-C, Chen S-J, Peng P-H, Tsang N-M, Lee L-Y, Liu S-C, Liang Y, Lee, Y-S, Hao S-P, Chang Y-S and Yu J-S*. (2010) Identification of candidate nasopharyngeal carcinoma serum biomarkers by cancer cell secretome and tissue transcriptome analysis: Potential usage of cystatin A for predicting nodal stage and poor prognosis. Proteomics 10, 2644-2660. [PubMed]
  120. Zhai H-L*, Chang Y-T, Wu C-C and Yu J-S*. (2010) An approach to the elimination of inter-individual variability in tumor detection. Analyst 135, 875 – 879. [PubMed]
  121. Chen J-S*, Chen K-T, Fan W-C, Yu J-S, Chang Y-S and Chan E-C*. (2010) Combined analysis of survivin autoantibody and carcinoembryonic antigen biomarkers for improved detection of colorectal cancer. Clin. Chem. Lab. Med. 48(5):719-25. [PubMed]
  122. Kao S-H, Hsu T-C, Yu J-S, Chen J-T, Li S-L, Lai W-X, Tzang B-S*. (2010) Proteomic analysis for the anti-apoptotic effects of cystamine on apoptosis-prone macrophage. J. Cell. Biochem. 110:660–670. [PubMed]
  123. ●● Wu C-C, Hsu C-W, Chen C-D, Yu C-J, Chang K-P, Dai D-I, Liu H-P, Su W-H, Chang Y-S, and Yu J-S*. (2010) Candidate serological biomarkers for cancer identified from the secretomes of 23 cancer cell lines and the human protein atlas. Mol. Cell. Proteomics 9, 1100-1117. [PubMed]
  124. Hung MS, Mao JH, Xu Z, Yang CT, Yu JS, Harvard C, Lin YC, Bravo DT, Jablons DM*, You L* (2011) Cul4A is an oncogene in malignant pleural mesothelioma. J. Cell. Mol. Med. 15(2), 350-358. [PubMed]
  125. ● Hsu R-M, Tsai M-H, Hsieh Y-J, Lyu P-C and Yu J-S*. (2010) Identification of MYO18A as a novel interacting partner of PAK2/PIX/GIT1 complex and its potential function in modulating epithelial cell migration. Mol. Biol. Cell 21(2), 287–301. [PubMed]
  126. Chang Y-H, Wu C-C, Chang K-P, Yu J-S, Liao P-C*. (2009) Cell secretome analysis using hollow fiber culture system leads to the discovery of CLIC1 protein as a novel plasma marker for nasopharyngeal carcinoma. J. Proteome Res. 8(12):5465-5474. [PubMed]
  127. Fang K-H, Kao H-K, Cheng M-H, Chang Y-L, Tseng N-M, Huang Y-C, Lee L-Y, Yu J-S, Hao S-P, Chang K-P*. (2009) Histological differentiation of primary oral squamous cell carcinomas in betel quid prevalent area. Otolaryngology-Head and Neck Surgery. 141(6):743-749. [PubMed]
  128. Wu H-Y, Tseng VSM, Chen L-C, Ping P, Chang Y-C, Tsay Y-G, Yu J-S and Liao P-C*. (2009) Combining alkaline phosphatase treatment and LTQ/Orbitrap high mass accuracy LC-MS data for the efficient and confident identification of protein phosphorylation. Anal. Chem. 81(18):7778-87. [PubMed]
  129. Wang C-L, Wang C-I, Liao P-C, Liang Y, Chen C-D, Liang Y, Chuang W-Y, Tsai Y-H, Chen H-C, Chang Y-S, Yu J-S, Wu C-C*, and Yu C-J*. (2009) Discovery of retinoblastoma-associated binding protein 46 as a novel prognostic marker for distant metastasis in non-small cell lung cancer by combined analysis of cancer cell secretome and pleural effusion proteome. J. Proteome Res. 8(10):4428-4440. [PubMed]
  130. Dong Y, Leu Y-L, Chien K-Y and Yu J-S*. (2009) Separation and determination of low abundant flavonoids in Scutellaria baicalensis Georgi by micellar eelectrokinetic capillary electrophoresis. Anal. Lett. 42(10):1444 -57. [Link]
  131. Chen L-C, Liu H-P, Li H-P, Hsueh C, Yu J-S, Liang C-L, Chang Y-S.* (2009) Thymidine phosphorylase mRNA stability and protein levels are increased through ERK-mediated cytoplasmic accumulation of hnRNP K in nasopharyngeal carcinoma cells. Oncogene 28(17):1904-15. [PubMed]
  132. ●● Chi L-M, Lee C-W, Chang K-P, Hao S-P, Lee H-M, Liang Y, Hsueh C, Yu C-J, Lee I-N, Chang Y-J, Lee S-Y, Yeh Y-M, Chang Y-S, Chien K-Y* and Yu J-S*. (2009) Enhanced interferon signaling pathway in oral cancer revealed by quantitative proteome analysis of microdissected specimens using 16O/18O labeling and integrated 2DLC-ESI-MALDI tandem MS. Mol. Cell. Proteomics 8:1453-1474. [PubMed]
  133. Lee LY, Wu CM, Wang CC, Yu JS, Liang Y, Huang KH, Lo CH, Hwang TL*. (2008) Expression of matrix metalloproteinases MMP-2 and MMP-9 in gastric cancer and their relation to claudin-4 expression. Histol. Histopathol. 2008 May;23(5), 515-521. [PubMed]
  134. Chang K-P, Hsu C-L, Chang Y-L, Tsang N-M, Chen C-K, Lee T-J, Tsao K-C, Huang C-G, Chang Y-S, Yu J-S, Hao S-P*. (2008) Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: A possible alternative for primary screening of nasopharyngeal carcinoma. Oral Oncol. 2008 Aug; 44(8), 784-792. [PubMed]
  135. Lin C-S, Liu N-T, Liao D-C, Yu J-S, Tsao C-H, Lin C-H, Sun C-W, Jane W-N, Tsay H-S, Chen JJ-W, Lai E-M, Lin N-S, Chang W-C, Lin C-C*. (2008) Differential protein expression of two photosystem II subunits, PsbO and PsbP, in an albino mutant of Bambusa edulis with chloroplast DNA aberration. J. Am. Soc. Hortic. Sci. 2008 March 1;133 (2), 270-277.
  136. Chen L-C, Hsueh C*, Tsang N-M, Liang Y, Chang K-P, Hao S-P, Yu J-S, Chang Y-S* (2008) Heterogeneous ribonucleoprotein K and thymidine phosphorylase are independent prognostic and therapeutic markers for nasopharyngeal carcinoma. Clin. Cancer Res. 2008 Jun 15;14(12): 3807-3813. [PubMed]
  137. Weng L-P, Wu C-C, Hsu B-L, Chi L-M, Liang Y, Tseng C-P, Hsieh L-L*, and Yu J-S*. (2008) Secretome-based identification of Mac-2 binding protein as a potential oral cancer marker involved in cell growth and motility. J. Proteome Res. 7(9):3765-3775. [PubMed]
  138. ● Chang K-P, Hao S-P, Chang JH, Wu C-C, Tsang N-M, Lee Y-S, Hsu CL, Ueng S-H, Liang Y, Liu SC, Liu YL, Wei PC, Chang Y-S and Yu J-S* (2008) Macrophage inflammatory protein-3 is a novel serum marker for nasopharyngeal carcinoma detection and prediction of treatment outcomes. Clin. Cancer Res. 14(21):6979-6987. [PubMed]
  139. Wu C-C, Huang Y-S, Lee L-Y, Liang Y, Tang R-P, Chang Y-S, Hsieh L-L*, and Yu J-S*. (2008) Overexpression and elevated plasma level of tumor-associated antigen 90K/Mac-2 binding protein in colorectal carcinoma. Proteomics-Clin. Appl. 2 (12), 1586–1595. [PubMed]
  140. Wu CC, Peng PH, Chang YT, Huang YS, Chang KP, Hao SP, Tsang NM, Yeh CT, Chang YS, and Yu JS* (2008) Identification of potential serum markers for nasopharyngeal carcinoma from a xenografted mouse model using Cy dye labeling combined with three-dimensional fractionation. Proteomics 8(17), 3605-3620. [PubMed]
  141. Wu C-C, Chen H-C, Chen S-J, Liu H-P, Hsieh Y-Y, Yu C-J, Tang R, Liang Y, Hsieh L-L*, Yu J-S* and Chang Y-S. (2008) Identification of collapsin response mediator protein-2 as a potential marker of colorectal carcinoma by comparative analysis of cancer cell secretomes. Proteomics 8(2), 316-332. [PubMed]
  142. Ni M-H, Wu C-C, Chan W-H, Chien K-Y and Yu J-S*. (2008) GSK-3 mediates the okadaic acid-induced modification of collapsin response mediator protein-2 in human SK-N-SH neuroblastoma cells. J. Cell. Biochem. 103(6), 1833-1848. [PubMed]
  143. Tse K-P, Tsang N-M*, Chen K-D, Liang Y, Li H-P, Hsueh C, Chang K-P, Yu J-S, Hao S-P, Hsieh L-L and Chang Y-S*. (2007) Single nucleotide polymorphism at -2518 of the MCP-1 gene regulatory region is associated with metastasis of nasopharyngeal carcinoma. Clin. Cancer Res. 13, 6320-6326. [PubMed]
  144. ● Huang W-C, Hsu R-M, Chi L-M, Leu Y-L, Chang Y-S and Yu J-S*. (2007) Selective downregulation of EGF receptor and downstream MAPK pathway in human cancer cell lines by active components partially purified from the seeds of Livistona chinesis R. Brown. Cancer Lett. 248, 137-146. [PubMed]
  145. Chen C-T, Chen W-Y, Tsai P-J, Chien K-Y, Yu J-S and Chen Y-C*. (2007) Rapid enrichment of phosphopeptides and phosphoproteins from complex samples using magnetic particles coated with alumina as the concentrating probes for MALDI MS analysis. J. Proteome Res. 6, 316-325. [PubMed]
  146. Ma DH*, Chen JK, Zhang F, Lin KY, Yao JY, Yu JS. (2006) Regulation of corneal angiogenesis in limbal stem cell deficiency. Prog. Retin. Eye Res. 25, 563-590. [PubMed]
  147. Tsai CL, Li HP, Lu YJ, Hsueh C, Laing Y, Chen CL, Tsao SW, Tse KP, Yu JS and Chang YS*. (2006). Activation of DNA methyltransferase 1 by Epstein-Barr Virus LMP1 involves JNK signaling. Cancer Res. 66, 11668-11676. [PubMed]
  148. Lu TJ, Lai WY, Huang CY, Hsieh WJ, Yu JS, Hsieh YJ, Chang WT, Leu TH, Chang WC, Chuang WJ, Tang MJ, Chen TY, Lu TL, Lai MD. (2006) Inhibition of cell migration by autophosphorylated mammalian sterile 20-like kinase 3 (MST3) involves paxillin and protein tyrosine phosphatase (PTP)-PEST. J. Biol. Chem. 281, 38405-38417. [PubMed]
  149. Kuo WL, Lee LY, Wu CM, Wang CC, Yu JS, Liang Y, Lo CH, Huang KH, Hwang TL. (2006) Differential expression of claudin-4 between intestinal and diffuse-type gastric cancer. Oncol. Rep. 16, 729-734. [PubMed]
  150. Chien KY, Chang YS, Yu JS, Fan L-W, Lee CW and Chi LM*. (2006) Identification of a new in vivo phosphorylation site in the cytoplasmic carboxyl terminus of EBV-LMP1 by tandem mass spectrometry. Biochem. Biophys. Res. Commun. 348, 47-55. [PubMed]
  151. Chang KP, Hao SP, Lin SY, Ueng SH, Pai PC, Tseng CK, Hsueh C, Hsieh MS, Yu JS, Tsang NM.* (2006) The 30-bp Deletion of Epstein-Barr Virus Latent Membrane Protein-1 Gene Has No Effect in Nasopharyngeal Carcinoma. Laryngoscope 116, 541-546. [PubMed]
  152. Hwang, T.-L.*, Liang, Y., Chien K.-Y., and Yu, J.-S. (2006) Overexpression and elevated serum levels of phosphoglycerate kinase 1 in pancreatic ductal adenocarcinma. Proteomics 6, 2259–2272. [PubMed]
  153. Hsuuw Y.D., Chang C.-K., Chan W.H.* and Yu J.-S. (2005) Curcumin prevents methylglyoxal-induced oxidative stress and apoptosis in mouse embryonic stem cells and blastocysts. J. Cell. Physiol. 205, 379-386. [PubMed]
  154. Peng, T.-I., Chang C.-J., Guo, M.-J., Wang, Y.-H., Yu, J.-S., Wu, H.-Y., and Jou, M.-J.* (2005) Mitochondrion-targeted photosensitizer enhances the photodynamic effect-induced mitochondrial dysfunction and apoptosis. Ann. N.Y. Acad. Sci. 1042, 419-428. [PubMed]
  155. ●● Wu, C.-C, Chien K.-Y., Tsang N-M, Chang K-P, Ho S-P, Tsao C-H, Chang Y-S, and Yu, J.-S.* (2005) Cancer cell-secreted proteomes as a basis for searching potential tumor markers - nasopharyngeal carcinoma as a model. Proteomics 5, 3173-3182. [PubMed]
  156. Tsai, I.-C., Hsieh, Y.-J., Lyu, P-C., and Yu, J.-S.* (2005) Anti-phosphopeptide antibody, P-STM as a novel tool for detecting mitotic phosphoproteins: Identification of lamins A and C as two major targets. J. Cell. Biochem. 94, 967–981. [PubMed]
  157. Fang, C.-Y., Chang, Y.-S., Chow, K.-P., Yu, J.-S., and Chang, H.-Y*. (2004) Construction and characterization of monoclonal antibodies specific to Epstein–Barr virus latent membrane protein 1. J. Immunol. Methods 287, 21-30. [PubMed]
  158. Chan W.-H.*, Wu, C.-C. and Yu J.-S. (2003) Curcumin inhibits UV irradiation-induced oxidative stress and apoptotic biochemical changes in human epidermoid carcinoma A431 cells. J. Cell. Biochem. 90, 327-338. [PubMed]
  159. ● Hsieh, Y.-J., Wu C.-C., Chang C.-J., and Yu J.-S.* (2003) Subcellular localization of Photofrin® determines the cell death phenotype of human epidermoid carcinoma A431 cells triggered by photodynamic therapy: When plasma membranes are the main targets. J. Cell. Physiol. 194, 363-375. [PubMed]
  160. Huang, H.C, Yu, J.-S., Tsay, C.C., Lin, J.H., Huang, S.Y., Fang, W.T., Liu, Y.C., Tzang, B.S., and Lee, W.C.* (2002) Purification and characterization of porcine testis 90-kDa heat shock protein (HSP90) as a substrate for various protein kinases. J. Protein Chem. 21, 111-121. [PubMed]
  161. Chi L-M*, Yu J.-S., and Chang Y.-S. (2002) Identification of protein kinase CK2 as a potent kinase of Epstein-Barr virus latent membrane protein 1. Biochem. Biophys. Res. Commun. 294, 586-591. [PubMed]
  162. ● Yu, J.-S.*, Tsai, H. -C., Wu, C.-C., Weng, L.-P., Li, S.-P., Chung P.-J., and Chang Y.-S. (2002) Induction of inducible nitric oxide synthase by the Epstein-Barr virus B95-8-derived LMP1 in Balb/3T3 cells promotes stress-induced cell death and impairs LMP1-mediated transformation. Oncogene 21, 8047-8061. [PubMed]
  163. Yu, J.-S.* Chang, S.-H, Chan, W.-H., and Chen, H.-C. (2001) Enzyme-linked immunosorbent assay for determination of p21-activated kinase activity. J. Biochem. 129, 243-251. [PubMed]
  164. ● Chan, W.-H., and Yu, J.-S.* and Yang, S.-D. (2000) Apoptotic signal cascade in photosensitized human epidermal carcinoma A431 cells. Involvement of singlet oxygen, c-Jun N-terminal kinase, caspase-3, and p21-activated kinase 2. Biochem. J. 351, 221-232. [PubMed]
  165. Chan, W.-H., and Yu, J.-S.* (2000) Inhibition of UV irradiation-induced oxidative stress and apoptotic biochemical changes in human epidermal carcinoma A431 cells by genistein. J. Cell. Biochem. 78, 73-84. [PubMed]
  166. Chan, W.-H., Yu, J.-S., Yang, S.-D.* (1999) PAK2 is cleaved and activation during hyperosmotic shock-induced apoptosis via a caspase-dependent mechanism. Evidence for the involvement of oxidative stress. J. Cell. Physiol. 178, 397-408. [PubMed]
  167. Yu, J.-S. (1998) Activation of protein phosphatase 2A by the Fe2+/ascorbate system. J. Biochem. 124, 225-230. [PubMed]
  168. Chan, W.-H., Yu, J. -S.*, and Yang, S. -D. (1998) Heat shock stress induces cleavage and activation of PAK2 in apoptotic cells. J. Protein Chem. 17, 485-494. [PubMed]
  169. Tang, T. -K., Chang, W.-C., Chan, W.-H., Yang, S. -D., Ni, M. -H., and Yu, J. -S.* (1998) Proteolytic cleavage and activation of PAK2 during UV irradiation-induced apoptosis in A431 cells. J. Cell. Biochem. 70, 442-454. [PubMed]
  170. ● Yu, J.-S.*, Chen, W.-J., Ni, M.-H., Chan, W.-H., and Yang, S.-D. (1998) Identification of the regulatory autophosphorylation site of autophosphorylation-dependent protein kinase : Evidence that auto-kinase belongs to a member of the p21-activated kinase family. Biochem. J. 334, 121-131. [PubMed]
  171. Yu, J.-S.*, Chan, W.-H., and Yang, S.-D. (1997) Selective interaction of of protein kinase FA/GSK-3a with membrane phospholipids. Biochem. Biophys. Res. Commun. 237, 331-335. [PubMed]
  172. Yu, J.-S.*, Chen, H.-C., and Yang, S.-D. (1997) Reversible tyrosine phosphorylation/dephosphorylation of proline-directed protein kinase FA/GSK-3a in A431 cells. J. Cell. Physiol. 171, 95-103. [PubMed]
  173. Ho, L.-T., Chou, Y.-C., Yu, J.-S., and Yang, S.-D.* (1996) Endothelin-1 and insulin induce inactivation of protein kinase FA/GSK-3a in a common signaling pathway. J. Biomed. Sci. 3, 275-279. [PubMed]
  174. Yang, S.-D.*, Yu, J.-S., Yang, C.-C., Lee, S.-C., Lee, T.-T., Ni, M.-H., Kuan, C.-Y., and Chen, H.-C. (1996) Overexpression of protein kinase FA/GSK-3a (a proline-directed protein kinase) correlates with human hepatoma dedifferentiation/progression. J. Cell. Biochem. 61, 238-245. [PubMed]
  175. Yu, J.-S., Chan, W.-H., and Yang, S.-D.* (1996) Activation of the ATP.Mg-dependent type-1 protein phosphatase by the Fe2+/ascorbate system. J. Protein Chem. 15, 455-460. [PubMed]
  176. Lee, T.-T., Ho, Y.-S., Yu, J.-S., and Yang, S.-D.* (1995) Overexpression of cellular activity and protein level of protein kinase FA/GSK-3 correlates with human thyroid tumor cell dedifferentiation. J. Cell. Biochem. 58, 474-480. [PubMed]
  177. Yang, S.-D.*, Yu, J.-S., Lee, T.-T, Ni, M.-H., Yang, C.-C., Ho, Y.-S., and Tsen, T.-Z. (1995) Association of protein kinase FA/GSK-3a (a particular member of proline-directed protein kinase family) with human cervical carcinoma dedifferentiation and progression. J. Cell. Biochem. 59, 143-150. [PubMed]
  178. Yang, S.-D.*, Yu, J.-S., Lee, T.-T., Yang, C.-C., Ni, M.-H., Yang, Y.-Y. (1995) Dysfunction of protein kinase FA/GSK-3a in lymphocytes of patients with schizophrenic disorder. J. Cell. Biochem. 59, 108-116. [PubMed] (SCI)
  179. Yu J.-S., Lee S.-C., and Yang, S.-D.* (1995) Effect of Mg2+ concentrations on phosphorylation/activation of phosphorylase b kinase by cAMP/Ca2+-independent, autophosphorylation-dependent protein kinase. J. Protein Chem. 14. 747-752. [PubMed]
  180. Yu, J.-S., and Yang, S.-D.* (1995) Phosphorylation/activation of phosphorylase b kinase by cAMP/Ca2+-independent, autophosphorylation-dependent protein kinase. Biochem. Biophys. Res. Commun. 207, 140-147. [PubMed]
  181. Huang, T.-J., Lee, T.-T., Lee, W.-C., Lai, Y-K., Yu, J.-S., and Yang. S.-D.* (1994) Autophosphorylation-dependent protein kinase phosphorylates Ser25, Ser38, Ser65, Ser71 and Ser411 in vimentin and thereby inhibits cytoskeletal intermediate filament assembly. J. Protein Chem. 13, 517-525. [PubMed]
  182. Yang, S.-D.*, Yu, J.-S., and Wen, Z.-D. (1994) Tumor promoter phorbol ester reversibly modulates tyrosine dephosphorylation/inactivation of protein kinase FA/GSK-3a in A431 cells. J. Cell. Biochem. 56, 550-558. [PubMed]
  183. Yang, S.-D.*, Yu, J.-S., Shiah, S.-G., and Huang, J.-J. (1994) Protein kinase FA/GSK-3a after heparin potentiation phosphorylates tau on the sites abnormally phosphorylated in Alzheimer's disease brain. J. Neurochem. 63, 1416-1425. [PubMed]
  184. Yu, J.-S., and Yang, S.-D.* (1994) Tyrosine dephosphorylation and concurrent inactivation of protein kinase FA/GSK-3 by genistein in A431 cells. J. Cell. Biochem. 56, 131-141. [PubMed]
  185. Yu, J.-S., and Yang, S.-D.* (1994) Okadaic acid, a serine/threonine phosphatases inhibitor induces tyrosine dephosphorylation/inactivation of protein kinase FA/GSK-3ain A431 cells. J. Biol. Chem. 269, 14341-14344. [PubMed] (NSC-81-0203-B007-509, NSC-82-0203-B007-29) (SCI)
  186. Yu, J.-S., and Yang, S.-D.* (1994) Protein kinase FA/glycogen synthase kinase-3 predominantly phosphorylates the in vivo site The97-Pro in brain myelin basic protein. Evidence for Thr-Pro and Ser-Arg-X-X-Ser as consensus sequences motif. J. Neurochem. 62, 1596-1603. [PubMed] (NSC-82-0203-B007-29) (SCI)
  187. Yang, S.-D.*, Song, J.-S., Yu, J.-S., and Shiah, S.-G. (1993) Protein kinase FA/GSK-3 phosphorylates tau on Ser235-Pro and Ser404-Pro that are abnormally phosphorylated in Alzheimer's disease brain. J. Neurochem. 61, 1742-1747. [PubMed]
  188. Yang, S.-D.*, Yu, J.-S., Liu, W.-K., and Yen, S.-H. (1993) Synergistic control mechanism for abnormal site phosphorylation of Alzheimer's diseased brain tau by kinase FA/GSK-3a. Biochem. Biophys. Res. Commun. 197, 400-406. [PubMed]
  189. Yu, J.-S., and Yang, S.-D.* (1993) Immunological and biochemical study on tissue and subcellular distributions of protein kinase FA (an activating factor of ATP.Mg-dependent protein phosphatase): A simplified and efficient procedure for high quantity purification from brain. J. Protein Chem. 12, 665-674. [PubMed]
  190. Yu, J.-S., and Yang, S.-D.* (1993) Identification and characterization of protein kinase FA/glycogen synthase kinase-3 in brain clathrin-coated vesicles. J. Neurochem. 60, 1714-1721. [PubMed]
  191. Lee, W.-C., Yu, J.-S., Yang, S.-D., and Lai, Y.-K.* (1992) Reversible hyperphosphorylation and reorganization of vimentin intermediate filaments by okadaic acid in 9L rat brain tumor cells. J. Cell. Biochem. 49, 378-393. [PubMed]
  192. Yang, S.-D.*, Yu, J.-S., Fong, Y.-L., and Liu, J.-S. (1992) The mechanism of activation of protein kinase FA (the activator of type-1 protein phosphatase) in brain synaptosomes. Biochem. Biophys. Res. Commun. 182, 129-136. [PubMed]
  193. Yang, S.-D.*, Yu, J.-S., and Lai, Y.-G. (1991) Identification and characterization of the ATP. Mg-dependent protein phosphatase activator (FA) as a microtubule protein kinase in the brain. J. Protein Chem. 10, 171-181. [PubMed]
  194. Yang, S.-D.*, Yu, J.-S., and Chen, H.-C. (1990) Regulation of protein kinase FA (a transmembrane signal of insulin and epidermal growth factor) in the brain. Biochem. Biophys. Res. Commun. 166, 267-272. [PubMed]
  195. Yang, S.-D.*, Yu, J.-S., and Hua, C.-W. (1990) On the mechanism of activation of protein kinase FA (an activating factor of ATP.Mg-dependent protein phosphatase) in brain myelin. J. Protein Chem. 9, 75-82. [PubMed]
  196. Yu, J.-S., and Yang, S.-D.* (1989) Identification and characterization of a Mn2+/phospholipid- dependent protein phosphatase from brain membranes. J. Protein Chem. 8, 499-517. [PubMed]
  197. Yang, S.-D.*, Ho, L.-T., Fung, T.-J., and Yu, J.-S. (1989) Insulin induces activation of kinase FA in membranes and thereby promotes activation of ATP.Mg-dependent phosphatase in Adipocytes. Biochem. Biophys. Res. Commun. 158, 762-768. [PubMed]
  198. Yang, S.-D.*, Fong, Y.-L., Yu, J.-S., and Liu, J.-S. (1987) Identification and characterization of a phosphorylation-activated, cAMP and Ca2+-independent protein kinase in brain. J. Biol. Chem. 262, 7034-7040. [PubMed]
  199. Yang, S.-D.*, Yu, J.-S., Liu, J.-S., Tzen, T.-C., and Wang, J.-K. (1987) The type-1 protein phosphatase activating factor FA is a membrane-associated protein kinase in brain, liver, heart and muscles. Biochem. Biophys. Res. Commun. 142, 38-46. [PubMed]
  200. Yang, S.-D.*, Liu, J.-S., Fong, Y.-L., Yu, J.-S., and Tzen, T.-C. (1987) Endogenous basic protein phosphatases in the brain myelin. J. Neurochem. 48, 160-166. [PubMed]
  201. Yang, S.-D.*, Yu, J.-S., and Fong, Y.-L. (1986) Purification and characterization of two inactive/latent protein phosphatases from pig brain. J. Biol. Chem. 261, 5590-5596. [PubMed]
  202. Yang, S.-D.*, Fong, Y.-L., and Yu, J.-S. (1984) Characterization of 3 distinct phosphoprotein phosphatase in mammalian tissues. J. Chin. Biochem. Soc. 13, 48-59.

　

(B) Book Chapters

1. Wen-Chuan Huang, Yann-Lii Leu, Jau-Song Yu*. (2011). Cancer and treatment with seeds of Chinese Fan Palm (Livistona chinensis R. Brown). In V. R. Preedy, R. R. Watson, V. B. Patel (Editors), Nuts & Seeds in Health and Disease Prevention (1st ed.) (pp 325-331). London, Burlington, San Diego: Academic Press is an imprint of Elsevier.

2. Yi-Ting Chen, Carol E. Parker, Hsiao-Wei Chen, Chien-Lun Chen, Dominik Domanski, Derek S. Smith, Chih-Ching Wu, Ting Chung, Kung-Hao Liang, Min-Chi Chen, Yu-Sun Chang, Christoph H. Borchers, and Jau-Song Yu. (2013) Chapter 10 "A Pipeline that Integrates the Discovery and Verification Studies of Urinary Protein Biomarkers Reveals Candidate Markers for Bladder Cancer". In Comprehensive Biomarker Discovery and Validation for Clinical Application. Peter Horvatovich, ‎Rainer Bischoff, ‎David E. Thurston (Editors), Royal Society of Chemistry (RSC).

　

Patents

1. Jau-Song Yu, Kai-Ping Chang. (2012) Method of detecting malignancy of nasopharyngeal carcinoma and a nasopharyngeal carcinoma malignancy biomarker. United States Patent, US8,148,059B2, Apr. 3, 2012. Patent period 2012/4/3~2029/10/30

2. Yi-Ting Chen, Jau-Song Yu, Chien-Lun Chen, Yu-Sun Chang (2013) Urine markers for detecting bladder cancer and a method for using the urine markers. Republic of China patent, I390204. Patent period: 2013/03/21-2030/2/10

3. Jau-Song Yu, Ya-Ting Chang, Chih-Ching Wu, Yi-Ming Shyr, Yu-Sun Chang (2013) A serological marker for detecting pancreatic cancer and a method for using the serological marker. Republic of China patent, I408370. Patent period: 2013/9/11~2031/5/18

4. Jau-Song Yu, Ming-Hung Tsai, Ling-Ling Hsieh (2014) Plasma Marker for Distal Metastasis in Colorectal Cancer. Republic of China patent, I444386. Patent period: 2014/7/11~2032/4/9

5. Chao-Sung Lai, Jau-Song Yu, Yu-Sun Chang, Po-Lung Yang, Tseng-Fu Lu, Yi-Ting Lin, Wen-Yu Chuang, Ting-Chun Yu, I-Shun Wang, Jyh-Ping Chen, Chou Chien (2014) Surface treatment method by using the NH3 plasma treatment to modify the sensing thin-film. United States Patent, US8741679 B2, June 3, 2014. Patent period 2014/6/3~2032/5/8

6. Jau-Song Yu, Ya-Ting Chang, Chih-Ching Wu, Yi-Ming Shyr, Yu-Sun Chang (2014) A method for detecting pancreatic cancer using the serological marker ULBP2. European patent, EP2525227B1, Patent period: 2/16/2015~5/16/2032 (Poland), 11/19/2014~5/16/2032 (France), 12/11/2014~5/16/2032 (Germany), 1/20/2015~5/16/2032 (Italy), 11/19/2014~5/16/2032 (United Kingdom), 1/13/2015~5/16/2032 (Spain)

7. Yi-Ting Chen, Jau-Song Yu, Chien-Lun Chen, Yu-Sun Chang (2016) Urine markers for detecting bladder cancer and kidney cancer. Republic of China patent, I522367. Patent period: 2016/2/21~2033/4/11

8. Jau-Song Yu, Yi-Ting Chen, Wei-Fan Chiang, Yu-Sun Chang, Lai-Chu See, Yung Chin Hsiao, Kai-Ping Chang. (2016) Apparatus and methods for detecting oral squamous cell carcinoma. US provisional application. No. 62309766 (application date: 2016/03/17)

9. Jau-Song Yu, Yi-Ting Chen, Wei-Fan Chiang, Yu-Sun Chang, Lai-Chu See, Yung Chin Hsiao, Kai-Ping Chang. (2017) Methods for cancer diagnosis and prognosis. International application (PCT) No. PCT/US17/22853 (application date: 2017/03/17)

10. Jau-Song Yu, Yi-Ting Chen, Wei-Fan Chiang, Yu-Sun Chang, Lai-Chu See, Yung Chin Hsiao, Kai-Ping Chang. (2019) Methods for cancer diagnosis and prognosis. Republic of China patent I522367. Patent period: 2019/2/21~2037/3/15

11. Err-Cheng Chan, Kuei-Tien Chen, Jau-Song Yu, Yu-Sun Chang Jinn-Shiun Chen. (2017) Serological markers for detecting colorectal cancer and their application for inhibiting colorectal cancer cells. United States Patent, US 9,835,636 B2, Dec. 5, 2017. Patent period: 2011/10/4-2031/10/3

12. Yu-Sun Chang, Jau-Song Yu, Yi-Ting Chen, Wei-Fan Chiang, Yung Chin Hsiao, Lai-Chu See, Kai-Ping Chang. (2020) Methods for cancer diagnosis and prognosis. European patent, EP3430406B1, Patent period: 2020/12/02~2037/3/17. (application date: 2017/03/17; application No.17767588.1)

13. Jau-Song Yu, Yi-Ting Chen, Wei-Fan Chiang, Yung-Chin Hsiao, Yu-Sun Chang, Lai-Chu See, Kai-Ping Chang. (2021) Methods for cancer diagnosis and prognosis. United States patent, US11187703B2, Patent period: 2021/11/30~2037/3/15. (application date: 2017/03/17; application No. 16084239)

　

Technology transfer

1. “Method for cancer diagnosis and prognosis” transferred to See & Treatment LTD (Time period: 2017/1/23-2023/1/22)

2. “Serum biomarker for pancreatic cancer and its application” transferred to See & Treatment LTD. (Time period: 2020/01/10~2030/01/10)

Selected Invited Speeches

  1. Integrated omics approaches for discovery of body fluid-accessible biomarkers for cancer. KHUPO 12TH Annual International Proteomics Conference, 2012/3/29, Seoul, Korea.
  2. Multiplexed quantification of 63 proteins in human urine by multiple reaction monitoring-based mass spectrometry for discovery of potential bladder cancer biomarkers. AOHUPO 6th Congress, 2012/5/7, Beijing, China
  3. Identification of dysregulated kinase-mediated pathways in hepatocellular carcinoma by a quantitative phosphoproteome approach. HUPO 12th Annual World Congress - 2013/9/17, Yokohama, Japan.
  4. Verification of oral cancer biomarkers and their translation to clinical settings. HUPO 15th Annual World Congress, 2016/9/18-21, Taipei, Taiwan.
  5. Verification of oral cancer biomarkers and their translation to clinical settings. The 26th Korea Genome Organization Annual Conference 2017, 2017/9/6, Seoul, Korea
  6. Development of salivary biomarkers for oral cancer. Mass Spectrometry and Proteomics 2018 (MSP2018), a joint conference of Asia-Oceania HUPO, Japanese Proteomics Society and Mass Spec Society of Japan, 2018/5/18, Osaka, Japan.
  7. Current status of cancer proteogenomics in Chang Gung University. Intl Proteogenome Workshop in Kyoto, 2018/5/19, Kyoto, Japan
  8. Development of saliva protein biomarkers to detect and monitor oral cancer. HUPO Connect 2020 (Virtual Conference), 2020/10/18

 

Click Num:
Print